To improve public confidence in clinical research, a number of public and private groups have called for a publicly accessible, comprehensive, and transparent registry of relevant information on clinical trials for drugs and biologics. The public and various entities within the medical community (health care providers, researchers, medical journal editors, pharmaceutical companies, health insurers, and regulators) have different expectations and perceived needs regarding a public clinical trial registry.



The IOM Committee on Clinical Trial Registries hosted a workshop on June 27, 2005, to obtain much-needed input from members of the public, public advocate groups, and the broader community of journal editors, pharmaceutical and biotech leaders, NIH, and the FDA. Participants discussed the data elements that have been at the core of debate and commented on issues of compliance and implementation of a national clinical trial registry.



Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Report inlcudes discussions at the workshop centered on the following five concepts, and are described within this report: 1) Purpose, 2) Which Trials to Include, 3) Delayed Disclosure Mechanism, 4) Reporting Results of Completed Trials, and 5) Compliance.



Table of Contents


Front Matter
1 Summary
2 The Need for Clinical Trial Registries
3 Current Registry Activities
4 Content of a Clinical Trial Registry
5 Implementation Issues
6 Conclusion and Next Steps
References
Appendix A Participants and Invited Experts - Between December 1, 2004 and June 27, 2005
Appendix B Workshop Agenda, Speakers, Panelists, and Participants - June 27, 2005
Appendix C Sec. 113 of the Food and Drug Administration Modernization Act of 1997; Guidance for Industry: Information Programs on Clinical Trials...
Appendix D Published Journal Editorials
Appendix E Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases
Appendix F Illustrative Data Fields for the Results Summary
Appendix G Biographical Sketches of Committee Members